Constellation Software excels in growth via acquisition in the vertical market software space, demonstrating consistent shareholder value creation over decades. CSU's decentralized operatorship and strategic acquisitions, including underperforming businesses, aim to generate attractive returns through niche market expertise. Financially, CSU boasts consistent EBITDA margins, manageable leverage, and robust free cash flow growth, making it a solid investment.
Any investor who has been in the market for the past two decades has mostly benefited from being overweight technology stocks.
Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concerns may affect patient adherence. Celldex's solid cash position and long runway reduce dilution risks, supporting the continued development of its pipeline.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JB John Brinckerhoff Oak Ridge Investments LLC | 18,621.73 | $1.84M | $131,519.93 | -$1.71M | -92.84% |